Patents by Inventor Kyriaki Dunussi-Joannopoulos
Kyriaki Dunussi-Joannopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140286959Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: November 2, 2012Publication date: September 25, 2014Applicant: PFIZER Inc.Inventors: Martin Hegen, Deborah Young, Heath Guay, Kyriaki Dunussi-Joannopoulos, Sudhakar Sridharan, Annette Diehl, Gail Comer, Margot O'Toole, Jean Beebe, Robert Fogel, Marek Honczarenko, David Beidler, Padmalatha S. Reddy, David J. von Schack
-
Patent number: 7976840Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: August 18, 2009Date of Patent: July 12, 2011Assignee: Genetics Institute, LLCInventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos
-
Publication number: 20110159011Abstract: Methods of detecting inflammatory disorders using IL- 1 isoforms are provided. Methods of treating an inflammatory disorder with an anti-IL-1 antibody are also provided. Methods of treating an inflammatory disorder with an anti-IL-1 antibody and at least one of an anti-IL-22 antibody, an anti-IL-17 antibody, or an anti-TNF? antibody are also provided.Type: ApplicationFiled: August 28, 2009Publication date: June 30, 2011Applicant: Wyeth LLCInventors: Yijun Carrier, Hak-Ling Ma, Kyriaki Dunussi-Joannopoulos, Quintus G. Medley
-
Publication number: 20110027273Abstract: Compositions and methods for treating autoimmune diseases are described. In particular, the use of B cell depleting agents and cytotoxic drug/B cell depleting agent conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) in treating autoimmune diseases is described. Combination therapies and compositions for treating autoimmune diseases, including the B cell depleting agents, conjugates and/or anti-cytokine agents, are also described.Type: ApplicationFiled: June 23, 2010Publication date: February 3, 2011Inventors: Kyriaki Dunussi-Joannopoulos, Anand P. Iyer
-
Publication number: 20100330089Abstract: The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.Type: ApplicationFiled: June 12, 2008Publication date: December 30, 2010Applicants: Wyeth, Trubion Pharmaceuticals Inc.Inventors: Nitin K. Damle, Lioudmila Tchistiakova, Kyriaki Dunussi-Joannopoulos, Sandy Alexander Simon, William Brady, Laura Sue Grosmaire, Jeffrey Alan Ledbetter
-
Publication number: 20100055091Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: August 18, 2009Publication date: March 4, 2010Inventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos
-
Patent number: 7601813Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 19, 2005Date of Patent: October 13, 2009Assignee: Genetics Institute, LLCInventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos
-
Patent number: 7521532Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: December 12, 2002Date of Patent: April 21, 2009Assignee: Genetics Institute, LLCInventors: Kyriaki Dunussi-Joannopoulos, Vincent Ling
-
Publication number: 20080241098Abstract: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).Type: ApplicationFiled: November 29, 2007Publication date: October 2, 2008Applicant: WYETHInventors: Deborah A. Young, Mary Collins, Kyriaki Dunussi-Joannopoulos, Richard Michael O'Hara, Marion T. Kasaian, Matthew J. Whitters
-
Publication number: 20070264257Abstract: Compositions and methods for treating autoimmune diseases are described. In particular, the use of B cell depleting agents and cytotoxic drug/B cell depleting agent conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) in treating autoimmune diseases is described. Combination therapies and compositions for treating autoimmune diseases, including the B cell depleting agents, conjugates and/or anti-cytokine agents, are also described.Type: ApplicationFiled: October 11, 2005Publication date: November 15, 2007Inventors: Kyriaki Dunussi-Joannopoulos, Anand Iyer
-
Publication number: 20060099635Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 19, 2005Publication date: May 11, 2006Applicant: Genetics Institute, LLCInventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos
-
Publication number: 20060039902Abstract: Methods and compositions for inhibiting interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating, ameliorating or preventing autoimmune or inflammatory disorders, including, e.g., inflammatory bowel disease (IBD), rheumatoid arthritis (RA), transplant/graft rejection, psoriasis, asthma, fibrosis, and systemic lupus erythematosus (SLE).Type: ApplicationFiled: August 5, 2005Publication date: February 23, 2006Inventors: Deborah Young, Mary Collins, Kyriaki Dunussi-Joannopoulos, Richard O'Hara, Marion Kasaian, Matthew Whitters
-
Publication number: 20040054158Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 12, 2002Publication date: March 18, 2004Inventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos
-
Publication number: 20040043040Abstract: The present invention relates to autologous tumor vaccines that include tumor cells which have been genetically engineered to secrete SDF-1&bgr;. Also featured are methods of making such tumor vaccines as well as methods for vaccinating and treating subjects having cancer with the vaccines of the present invention.Type: ApplicationFiled: May 9, 2003Publication date: March 4, 2004Inventor: Kyriaki Dunussi-Joannopoulos
-
Patent number: 6521749Abstract: The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode GL50 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing GL50 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GL50 gene has been introduced or disrupted. The invention still further provides isolated GL50 polypeptides, fusion proteins, antigenic peptides and anti-GL50 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: September 21, 2000Date of Patent: February 18, 2003Assignee: Genetics Institute, Inc.Inventors: Vincent Ling, Kyriaki Dunussi-Joannopoulos